Paratek Signs an Exclusive License Agreement with Almirall for SEYSARA (sarecycline)
Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections
Shots:
- Paratek to get exclusive rights to develop and commercialize sarecycline and will receive royalties on net sales of the product in the greater China region. Additionally, the companies are developing the product for ROW with profit split. Almirall to get rights to SEYSARA for acne in the US
- In Mar 2017, Paratek granted exclusive the US rights of SEYSARA to Allergan. In 2018, Almirall acquired dermatology business portfolio including SEYSARA from Allergan
- SEYSARA (sarecycline) is a once daily oral therapy targeted for the treatment of moderate to severe acne vulgaris. Almirall plans to develop the product in China for acne with NDA submission to the NMPA in 2023
Click here to read full press release/ article | Ref: Globe News wire | Image: Twitter